PET心肌灌注显像剂

由于PET在心肌灌注显像方面具有高分辨率、高灵敏度、低组织衰减和心肌血流定量等优势而使得PET心肌灌注显像剂的研究日益受到关注。本文介绍了目前已经应用于临床的PET心肌灌注显像剂的情况,分别综述了 ¹⁸F 标记和其他正电子核素标记的PET心肌灌注显像剂的研究进展,重点讨论了几种亲脂性阳离子类和线粒体复合物Ⅰ(MC-Ⅰ)抑制剂类 ¹⁸F 标记心肌灌注显像剂,特别是近年取得突破性进展的MC-Ⅰ抑制剂类心肌灌注显像剂(如BMS-747158-02和[¹⁸F]FP1OP),介绍了各类PET心肌灌注显像剂的生物性能、心肌摄取机制,对其优缺点进行比较,并对PET心肌灌注显像剂的应用前景进行了展望。     

正电子发射断层显像剂[18F]FET前体药物的合成

以L-酪氨酸为原料,设计并合成了6个正电子发射断层显像剂[18F]FET前体药物,其中5个未见文献报道,其结构经1H NMR,IR,MS和元素分析表征.     

Comparison of [18F]F-CNBI and [18F]F-CNPIFE as Positron Emission Tomography Probes for Noninvasive Imaging of Glycogen Synthase Kinase-3 in Normal Mice

Glycogen synthase kinase-3 α/β is involved in dysregulation of neuronal tau protein in Alzheimer's disease (AD). There is an unmet clinical need for a blood-brain barrier (BBB) permeable positron emission tomography (PET) probe for imaging of GSK-3α/β in the brain to understand the pathogenesis of AD. Herein, we synthesized two PET probes, [¹⁸F]F-CNBI and [¹⁸F]F-CNPIFE, and evaluated their BBB permeability and affinity towards GSK-3α/β. [¹⁹F]F-CNPIFE showed higher in-vitro binding towards GSK-3α/β (IC₅₀=19.4±2.5 nM; n=3, for GSK-3α, IC₅₀=19.4±3.8 nM; n=3, for GSK-3β) compared to [¹⁹F]F-CNBI (IC₅₀=107.6±26.0 nM; n=4, for GSK-3α, IC₅₀=105.3±18.2 nM; n=3, for GSK-3β). [¹⁸F]F-CNPIFE showed 9.5-fold higher brain uptake than [¹⁸F]F-CNBI, in normal FVB/NJ mice, which was increased by additional 1.5-fold on co-administration of [¹⁹F]F-CNPIFE with respect to [¹⁸F]F-CNBI. Overall, [¹⁸F]F-CNPIFE is a promising PET probe for GSK-3α/β imaging and warrants further evaluation in an AD mouse model.     

[18F]Ethenesulfonyl Fluoride as a Practical Radiofluoride Relay Reagent

Fluorine-18 is the most utilized radioisotope in positron emission tomography (PET), but the wide application of fluorine-18 radiopharmaceuticals is hindered by its challenging labelling conditions. As such, many potentially important radiotracers remain underutilized. Herein, we describe the use of [¹⁸F]ethenesulfonyl fluoride (ESF) as a novel radiofluoride relay reagent that allows radiofluorination reactions to be performed in minimally equipped satellite nuclear medicine centres. [¹⁸F]ESF has a simple and reliable production route and can be stored on inert cartridges. The cartridges can then be shipped remotely and the trapped [¹⁸F]ESF can be liberated by simple solvent elution. We have tested 18 radiolabelling precursors, inclusive of model and clinically used structures, and most precursors have demonstrated comparable radiofluorination efficiencies to those obtained using a conventionally dried [¹⁸F]fluoride source.     

Site‐Selective,Late‐Stage C−H 18F‐Fluorination on Unprotected Peptides for Positron Emission Tomography Imaging

Peptides are often ideal ligands for diagnostic molecular imaging due to their ease of synthesis and tuneable targeting properties. However, labelling unmodified peptides with ¹⁸F for positron emission tomography (PET) imaging presents a number of challenges. Here we show the combination of photoactivated sodium decatungstate and [¹⁸F]‐N‐fluorobenzenesulfonimide effects site‐selective ¹⁸F‐fluorination at the branched position in leucine residues in unprotected and unaltered peptides. This streamlined process provides a means to directly convert native peptides into PET imaging agents under mild aqueous conditions, enabling rapid discovery and development of peptide‐based molecular imaging tools.     

Sulfonyl Fluoride‐Based Prosthetic Compounds as Potential 18F Labelling Agents

Nucleophilic incorporation of [¹⁸F]F^? under aqueous conditions holds several advantages in radiopharmaceutical development, especially with the advent of complex biological pharmacophores. Sulfonyl fluorides can be prepared in water at room temperature, yet they have not been assayed as a potential means to ¹⁸F‐labelled biomarkers for PET chemistry. We developed a general route to prepare bifunctional 4‐formyl‐, 3‐formyl‐, 4‐maleimido‐ and 4‐oxylalkynl‐arylsulfonyl [¹⁸F]fluorides from their sulfonyl chloride analogues in 1:1 mixtures of acetonitrile, THF, or tBuOH and Cs[¹⁸F]F/Cs₂CO_3(aq.) in a reaction time of 15 min at room temperature. With the exception of 4‐N‐maleimide‐benzenesulfonyl fluoride ( 3 ), pyridine could be used to simplify radiotracer purification by selectively degrading the precursor without significantly affecting observed yields. The addition of pyridine at the start of [¹⁸F]fluorination (1:1:0.8 tBuOH/Cs₂CO_3(aq.)/pyridine) did not negatively affect yields of 3‐formyl‐2,4,6‐trimethylbenzenesulfonyl [¹⁸F]fluoride ( 2 ) and dramatically improved the yields of 4‐(prop‐2‐ynyloxy)benzenesulfonyl [¹⁸F]fluoride ( 4 ). The N‐arylsulfonyl‐4‐dimethylaminopyridinium derivative of 4 ( 14 ) can be prepared and incorporates ¹⁸F efficiently in solutions of 100 % aqueous Cs₂CO₃ (10 mg mL^?1). As proof‐of‐principle, [¹⁸F] 2 was synthesised in a preparative fashion [88(±8) % decay corrected (n=6) from start‐of‐synthesis] and used to radioactively label an oxyamino‐modified bombesin(6–14) analogue [35(±6) % decay corrected (n=4) from start‐of‐synthesis]. Total preparation time was 105–109 min from start‐of‐synthesis. Although the ¹⁸F‐peptide exhibited evidence of proteolytic defluorination and modification, our study is the first step in developing an aqueous, room temperature ¹⁸F labelling strategy.     

Chemistry for Positron Emission Tomography: Recent Advances in 11C‐, 18F‐, 13N‐, and 15O‐Labeling Reactions

Positron emission tomography (PET) is a molecular imaging technology that provides quantitative information about function and metabolism in biological processes in vivo for disease diagnosis and therapy assessment. The broad application and rapid advances of PET has led to an increased demand for new radiochemical methods to synthesize highly specific molecules bearing positron‐emitting radionuclides. This Review provides an overview of commonly used labeling reactions through examples of clinically relevant PET tracers and highlights the most recent developments and breakthroughs over the past decade, with a focus on ¹¹C, ¹⁸F, ¹³N, and ¹⁵O.     

Synthesis and Derivatization of 1,1‐[18F]Difluorinated Alkenes

A general method for the synthesis of 1,1‐[¹⁸F]difluorinated alkenes from [¹⁸F]fluoride is reported. This transformation is highly regioselective giving the desired ¹⁸F‐fluoroalkenes with radiochemical purities of up to 77 % within 20 minutes and a molar activity (A_m) of 1 GBq μmol^?1. The transformations are operationally simple to perform and were readily translated onto a commercial automated synthesis unit. The resultant 1,1‐[¹⁸F]difluorinated alkene motif is prevalent in numerous drug molecules, and this is the first general method to synthesize this motif with fluorine‐18. ¹⁸F‐fluorinated alkenes are excellent building blocks and participate in a number of post‐labeling transformations to access a range of ¹⁸F‐perfluorinated functional groups that have never before been radiolabeled with non‐carrier‐added [¹⁸F]fluoride. This method considerably expands the range of ¹⁸F‐motifs accessible to radiochemists.     

Preparation,Optimisation, and In Vitro Evaluation of [18F]AlF-NOTA-Pamidronic Acid for Bone Imaging PET

[¹⁸F]sodium fluoride ([¹⁸F]NaF) is recognised to be superior to [⁹⁹mTc]-methyl diphosphate ([^99mTc]Tc-MDP) and 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG) in bone imaging. However, there is concern that [¹⁸F]NaF uptake is not cancer-specific, leading to a higher number of false-positive interpretations. Therefore, in this work, [¹⁸F]AlF-NOTA-pamidronic acid was prepared, optimised, and tested for its in vitro uptake. NOTA-pamidronic acid was prepared by an N-Hydroxysuccinimide (NHS) ester strategy and validated by liquid chromatography-mass spectrometry analysis (LC-MS/MS). Radiolabeling of [¹⁸F]AlF-NOTA-pamidronic acid was optimised, and it was ensured that all quality control analysis requirements for the radiopharmaceuticals were met prior to the in vitro cell uptake studies. NOTA-pamidronic acid was successfully prepared and radiolabeled with ¹⁸F. The radiolabel was prepared in a 1:1 molar ratio of aluminium chloride (AlCl₃) to NOTA-pamidronic acid and heated at 100 °C for 15 min in the presence of 50% ethanol (v/v), which proved to be optimal. The preliminary in vitro results of the binding of the hydroxyapatite showed that [¹⁸F]AlF-NOTA-pamidronic acid was as sensitive as [¹⁸F]sodium fluoride ([¹⁸F]NaF). Normal human osteoblast cell lines (hFOB 1.19) and human osteosarcoma cell lines (Saos-2) were used for the in vitro cellular uptake studies. It was found that [¹⁸F]NaF was higher in both cell lines, but [¹⁸F]AlF-NOTA-pamidronic acid showed promising cellular uptake in Saos-2. The preliminary results suggest that further preclinical studies of [¹⁸F]AlF-NOTA-pamidronic acid are needed before it is transferred to clinical research.     

Synthesis of 18F‐Difluoromethylarenes from Aryl (Pseudo) Halides

A general method for the synthesis of [¹⁸F]difluoromethylarenes from [¹⁸F]fluoride for radiopharmaceutical discovery is reported. The method is practical, operationally simple, tolerates a wide scope of functional groups, and enables the labeling of a variety of arenes and heteroarenes with radiochemical yields (RCYs, not decay‐corrected) from 10 to 60 %. The ¹⁸F‐fluorination precursors are readily prepared from aryl chlorides, bromides, iodides, and triflates. Seven ¹⁸F‐difluoromethylarene drug analogues and radiopharmaceuticals including Claritin, fluoxetine (Prozac), and [¹⁸F]DAA1106 were synthesized to show the potential of the method for applications in PET radiopharmaceutical design.     

正电子发射显像剂O-(2-[18F]氟乙基)-L-酪氨酸的新型前体的合成

设计合成了5种新型正电子发射断层显像剂[O-(2-[¹⁸F]氟乙基)-L-酪氨酸的前体化合物：N-叔丁氧羰基-O-(2-甲磺酰/对硝基苯磺酰)-氧乙基-L-酪氨酸甲酯(9a,11a)和N-叔丁氧羰基-O-(2-甲磺酰/对甲苯磺酰/对硝基苯磺酰)-氧乙基-L-酪氨酸叔丁酯(9b,10b,11b)。 这些化合物以L-酪氨酸为原料,先与甲醇发生酯化反应或与乙酸叔丁酯进行酯交换,再用叔丁氧羰基保护氨基,最后以碳酸钾为碱、18-冠-6为相转移催化剂与乙二醇的磺酸酯在丙酮溶液中加热回流形成目标化合物,总收率为30%～67%。     

Rapid Aqueous Late‐Stage Radiolabelling of [GaF3(BnMe2‐tacn)] by 18F/19F Isotopic Exchange: Towards New PET Imaging Probes

A simple and rapid method for ¹⁸F radiolabelling of [GaF₃(BnMe₂‐tacn)] by ¹⁸F/¹⁹F isotopic exchange is described. The use of MeCN/H₂O or EtOH/H₂O (75:25) and aqueous [¹⁸F]F^? (up to 200 MBq) with heating (80 °C, 10 min) gave 66±4 % ¹⁸F incorporation at a concentration of 268 nm , and 37±5 % ¹⁸F incorporation at even lower concentration (27 nm ), without the need for a Lewis acid promoter. A solid‐phase extraction method was established to give [Ga¹⁸F¹⁹F₂(BnMe₂‐tacn)] in 99 % radiochemical purity in an EtOH/H₂O mixture.     

Site‐Selective,Late‐Stage C−H 18F‐Fluorination on Unprotected Peptides for Positron Emission Tomography Imaging

Peptides are often ideal ligands for diagnostic molecular imaging due to their ease of synthesis and tuneable targeting properties. However, labelling unmodified peptides with ¹⁸F for positron emission tomography (PET) imaging presents a number of challenges. Here we show the combination of photoactivated sodium decatungstate and [¹⁸F]‐N‐fluorobenzenesulfonimide effects site‐selective ¹⁸F‐fluorination at the branched position in leucine residues in unprotected and unaltered peptides. This streamlined process provides a means to directly convert native peptides into PET imaging agents under mild aqueous conditions, enabling rapid discovery and development of peptide‐based molecular imaging tools.     

Synthesis and Preliminary Evaluation of 1-[^18F]Fluoro-1-deoxy-2,5-anhydro-D-mannitol as a PET Radiotracer for Breast Cancer Imaging

1-[^18F]Fluoro-l-deoxy-2,5-anhydro-D-mannitol （3, ^18F-FDAM） has been synthesized in 6 steps starting from 2,5-anhydro-D-mannitol （2,5-AM） and evaluated as a new radiotracer for PET imaging of MCF-7 breast tumor. The result of PET imaging study showed that 3 displayed a slightly higher uptake by breast tumor in comparison with the normal breast tissue, implying the possibility of development of PET radiotraeers based on targeting fructose transporters.